Lycia Therapeutics raised $75 million in private equity offering
Lycia Therapeutics, a Delaware biotechnology corporation, completed a $75 million private equity offering under Regulation D Rule 506(b), with 16 investors participating. The offering was fully subscribed as of June 10, 2026, the date of the first sale. No sales or finders' compensation was paid.
Key facts
- $75,000,000 total raised
- 16 investors
- Rule 506(b) exemption
- June 10, 2026 first sale date
- 100% of target sold
Why it matters
The funding allows Lycia to advance its biotechnology development and operations without dilution from a registered public offering.
Share
Derived from D filed 2026-06-25. Not investment advice. View the source filing on SEC.gov →